Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
1.5 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Anticancer Fund (ACF)
EU Transparency Register
404359320127-95 First registered on 30 Dec 2015
Goals / Remit
The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.
The Anticancer Fund is a foundation of public utility with an international reach that focuses on the cure of cancer patients by:
- Developing promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatments.Main EU files targeted
Europe’s Beating Cancer Plan
Horizon: EU4Health and Missions
New Pharmaceutical Strategy
Special Committee on Cancer (BECA)
MAC Group (Members of Parliament Against Cancer)
Cancer related policies
Research and clinical trials
Market authorisation for innovative medicines
Revision of the Pharmaceutical LegislationAddress
Head Office
Brusselsesteenweg 11
Meise 1860
BELGIUMEU Office
Brusselsesteenweg 11
Meise 1860
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 75% 1 50% 1 25% 1 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
https://www.icrpartnership.org/
https://www.europeancancer.org/
https://bigagainstbreastcancer.org/collaborations/patient-advocates/ (BIG: Patient Partnership Initiative)
https://www.ovacure.org/en/ (Scientific Board)
https://c-path.org/programs/cdrc/ (Cure Drug Repurposing Collaboratory)
https://consilium-scientific.org/ (Advisory Board)Member organisations
None declared
-
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
1,117,631€
Major funding types in closed year
EU funding, Other, Donations
Funding types "other" information
Major contributions in closed year
Type Name Amount Contribution Baltisse NV 250,000€ Contribution EATRIS for REMEDI4ALL 149,603€ Grant EATRIS 149,603€ Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
Cancer
Communication activities
1. Member of the Repurposing Observatory Group (RepOG)
2. Targeted EU Contact Program on cancer related policy: Webinar to raise awareness among policymakers, researchers, physicians and patients of the potential of repurposed drugs in the treatment of cancer against the backdrop of the COVID-19 pandemic.
3. Stakeholder Contact Group EBCP
4. Since 2017, the ACF was invited for STAMP meetings on the topic of drug repurposing. The ACF actively contributed to drafting the framework proposal for drug repurposing.
5. Slovenia invited ACF to present on the topic during a joint meeting between the EU-Directors for Pharmaceutical Policy and the Pharmaceutical Committee of the European Commission (8 July 2021). The meeting was attended by more than 110 representatives from the European Commission, 26 EU Member States, Norway, Iceland, the European Medicines Agency (EMA), the Council of Europe (European Directorate for the Quality of Medicines), as well as WHO Europe and invited distinguished international experts.
6. Since 2019, the ACF has been providing feedback to the commission through surveys and public consultations on Europe’s beating cancer plan, the cancer mission, the pharmaceutical strategy, Revision of EU rules on medicines for children and rare diseases and on the revision of the pharmaceutical legislation.
On 21 may 2021, ACF was invited to participate in the Pharmaceutical Committee on the subject of: “Future proofing of the legislation and incentives for innovation that reaches the patient”.
7. The ACF formulated its recommendations to the Mission Board and had F-2-F meetings with different MEPs. The ACF was also amongst the experts involved in the consultation process within the special committee on beating cancer (BECA) that provided policy recommendations (https://www.anticancerfund.org/en/lab-life-transforming-childhood-adolescent-and-rare-cancer-care ). ACF participates in the Belgian European Beating Cancer Plan Mirror group.
8. The ACF has been highlighting the benefits of drug repurposing to policy makers for many years. On the 1st of September 2022, REMEDi4ALL was launched, an ambitious EU-funded research initiative to drive forward the repurposing of medicines in Europe. The ACF is one of the participating organisations.Other activities
Participation: Virtual Townhall Meeting for the Europe's Beating Cancer Plan (10 September 2020)
Panelist invited by Olga Solomon: Pharmaceutical Strategy for Europe - Building a comprehensive pharmaceutical policy to address today’s challenges and tomorrow’s realities - DG SANTE Session - European Health Forum Gastein 2020 (1 October 2020)
Meetings
Meetings
None declared